Robert J. Israel

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Researcher

UAMS

Also affiliated: University of Southern California (2010); Brigham and Women's Hospital (2024); City Of Hope National Medical Center (2009); Memorial Sloan Kettering Cancer Center (1990); Cornell University (1986); North Shore University Hospital (1986); Bausch Health (United States) (2017–2023); Progenics Pharmaceuticals (United States) (2006–2014); Epix Pharmaceuticals (United States) (2024); Xanadu Quantum Technologies (Canada) (2020); Ortho Clinical Diagnostics (United States) (2019); Hartford Financial Services (United States) (2024); University of South Alabama (2024)

Faculty Researcher

16 h-index 59 pubs 1,041 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Robert J. Israel's research has focused on pharmacological interventions and clinical studies, with a notable emphasis on treatments for opioid-induced constipation and respiratory conditions. He has investigated the efficacy and safety of subcutaneous methylnaltrexone in both cancer and non-cancer patients, analyzing variables across multiple studies. Additionally, Israel has explored the use of ribavirin aerosol for treating SARS-CoV-2 in hospitalized adults, including a randomized, placebo-controlled study on its safety and pharmacokinetics. His work also includes an analysis of methylnaltrexone's central nervous system effects in patients with brain metastases and a thorough QT study evaluating the cardiac safety of amiselimod.

His scholarship metrics include an h-index of 16, with 59 total publications and over 1,033 citations. Israel has collaborated with researchers such as Sara C. Shalin, Belin F Bodies, and Thomas C Myers at the University of Arkansas for Medical Sciences. His most recent publication was in 2024, indicating recent activity in his research pursuits.